Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen total Product Sales — United States ($M) ($M)
Form 10-Q / 10-K Note 2 & Form 8-K Product Sales Detail
Latest, Q2 2026
6,990
Period ended Jun 30, 2026
Change on a year earlier
+10.5%
6,324 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Product Sales — United States ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 6,990 | +10.5% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 5,773 | +2.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 6,919 | +6.3% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 6,751 | +12.9% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 6,324 | +8.3% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 5,662 | +13.9% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 6,509 | +10.9% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 5,979 | +27.5% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 5,840 | +23.3% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,973 | +25.1% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,870 | +22.4% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 4,691 | +5.0% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 4,736 | +6.5% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 3,975 | -1.5% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 4,794 | +7.7% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 4,466 | -2.0% | Form 10-Q (filed 2023-10-31) ↗ |
| Q2 2022 | Jun 30, 2022 | 4,446 | +1.6% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 4,037 | +3.4% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 4,451 | -4.5% | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2021 | Sep 30, 2021 | 4,558 | -1.3% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 4,374 | -1.2% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 3,903 | -8.8% | Form 10-Q (filed 2022-04-28) ↗ |
| Q4 2020 | Dec 31, 2020 | 4,660 | +6.7% | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 4,618 | +14.6% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 4,428 | +6.9% | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 4,279 | +7.2% | Form 10-Q (filed 2021-04-28) ↗ |
| Q4 2019 | Dec 31, 2019 | 4,369 | -6.1% | Form 10-K (filed 2022-02-16) ↗ |
| Q3 2019 | Sep 30, 2019 | 4,029 | -5.4% | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2019 | Jun 30, 2019 | 4,142 | -5.2% | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2019 | Mar 31, 2019 | 3,991 | -3.8% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 4,655 | +6.9% | Form 10-K (filed 2021-02-09) ↗ |
| Q3 2018 | Sep 30, 2018 | 4,260 | -0.9% | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2018 | Jun 30, 2018 | 4,367 | -0.4% | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2018 | Mar 31, 2018 | 4,147 | +1.3% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 4,353 | – | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 4,297 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jun 30, 2017 | 4,386 | – | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2017 | Mar 31, 2017 | 4,095 | – | Form 10-Q (filed 2018-04-25) ↗ |
Breakdown
What makes up total product sales — united states ($m)
Cite this data
StockData. (2026). Amgen Total Product Sales — United States ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_total_us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.